Background The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has
been a major advance for stroke prevention in atrial fibrillation (AF). Patients and clinicians …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …

Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …

Atrial fibrillation (AF) confers a significant risk of stroke or systemic thromboembolism. Oral
anticoagulation is the most effective therapy for AF-related stroke prevention. A decision to …

Background: To review data from the pivotal phase III trials evaluating the efficacy and safety
of direct oral anticoagulants (DOACs) versus warfarin for stroke prevention in patients with …

Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared
non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …

Objective To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …

The aim of our article is to provide a concise review for clinicians entailing the main studies
that evaluated the efficacy and safety of target-specific oral anticoagulants (TSOAs) for …

To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke
in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by …